>given how tyzeka is selling, I don't think the royalty rate is that critical to evaluating the restructuring - at least near to mid-term<
I respectfully disagree—the royalty rate is very important to know because Tyzeka can still become a decent-selling drug and the rest of IDIX’s non-cash assets are speculative.
That IDIX might get acquired before Tyzeka sales ramp up does not change the relevance of knowing the present value of the royalty stream. To the contrary, the Tyzeka royalty rate will almost certainly have to be disclosed for there to be a shareholder vote on a proposed acquisition.
Market Data 
Markets 
AI
